Porsolt & Partners Pharmacology will be at BIO 2010 in Chicago this May to inform its sponsors and potential clients of the company's latest developments and research. The French contract research organization (CRO) has specialized in preclinical in vivo pharmacology since 1984, performing efficacy and safety studies in various domains such as the central nervous system, cardiovascular, respiratory, gastrointestinal, and renal/urogenital systems. Porsolt & Partners will be at booth 3712 with Atlanpole Biotherapies from May 3 to 6, 2010.

Porsolt's clients have used data from its studies to advance their drug candidates towards clinical development. The company has worked with large international pharmaceutical companies and with major biotechnology companies. BIO 2010 is also a chance for the company to hear new requests, solidify developing contracts, and grab the attention of future clients. This exhibition of specialists allows the company's team of experts to improve their knowledge by observing market trends.

The company is a privately owned CRO specialized in the preclinical evaluation of novel substances for their potential therapeutic activity (efficacy pharmacology) and adverse effects (safety pharmacology). Concerning the latter, Porsolt & Partners Pharmacology is Grade A certified and fully compliant with the highest international standards of Good Laboratory Practice (GLP). For Porsolt, quality and ethics go beyond compliance with international standards. It is a strong commitment, a state of mind, shared by the entire team. With 85% of its business conducted for clients outside France, Porsolt & Partners Pharmacology is a service provider for the international pharmaceutical industry, and of its more than 100 clients, 13 are among the world's top 20 companies

Porsolt & Partners Pharmacology provides specialized services in a wide variety of therapeutic areas including the central nervous system, pain & inflammation, the cardiovascular, respiratory, gastro-intestinal, renal and urogenital systems, metabolism and obesity. The company has obtained an international reputation for its expertise in physio-pathological models and tailored procedures for evaluating substances for the treatment of Alzheimer's disease, epilepsy, neuropathic pain, cardiac insufficiency, hypertension and arrhythmia, eating disorders, and for problems of drug dependence and abuse. To reinforce its array tests, Porsolt & Partners Pharmacology maintains an active internal research program and has published over 100 scientific articles in international journals and books. Its status as a scientific research establishment has been officially recognized by the French Ministry for Research.

With an average growth of over 15% per year over the last 10 years, Porsolt & Partners Pharmacology is currently starting construction of a new 6 000 m2 research center on a nearby site, scheduled for completion on 2010.

Porsolt & Partners Pharmacology employs a staff of 72 on two sites: business and scientific administration in Boulogne-Billancourt (Paris region) and the research staff at its research center in the Mayenne province near Laval.

For more information, visit: www.porsolt.com.

Source: web of Pharmaoutsourcing